Clinical trials: Tislelizumab
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
HER2-positive Gastric Cancer, Immunotherapy
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
At present, there is no anti-HER2 therapy recommended by guidelines for second-line treatment of advanced gastric cancer with HER2-positive or HER2-overexpression, and combined with anti-angiogenic drugs are mainly used.
- Trial name
- NCT05982834
- Testing
- Disitamab Vedotin combined with fruquintinib and Tislelizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced…
- Trial name
- NCT05508100
- Testing
- IO-108, IO-108 + pembrolizumab, IO-108 + tislelizumab
- Where
- 14 sites in China
- Volunteers
- 38 people
- Sponsor
- Immune-Onc Therapeutics
Astrocytoma of Brain
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years)…
- Trial name
- NCT05518994
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Provincial People's Hospital
Non-Small Cell Lung Cancer
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
This study will be conducted at Fujian Provincial Cancer Hospital. Its main goals are to evaluate the progression-free survival (PFS) and safety of postoperative immunotherapy combined with radiotherapy in patients with high-risk…
- Trial name
- NCT07320105
- Testing
- Tislelizumab + platinum-based chemotherapy, Tislelizumab + platinum-based chemotherapy + focal radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
Liver Metastases
Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Liver metastases are one of the most common sites of metastasis in advanced gastric cancer. Chemotherapy remains the mainstay of treatment for these patients, but combination chemotherapy has encountered a bottleneck in improving…
- Trial name
- NCT05325528
- Testing
- Tislelizumab in Combination with Oxaliplatin and Tegafur
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
mCRPC
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior…
- Trial name
- NCT07389187
- Testing
- LC-K76, Tislelizumab, Standard Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Changzheng Hospital
Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
For limited-stage small cell lung cancer (SCLC), surgical treatment is recommended for patients with T1-2N0M0 (I-IIA) by guidelines.
- Conditions
- Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer
- Trial name
- NCT07109401
- Testing
- Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Recurrent Glioblastoma
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive…
- Trial name
- NCT05540275
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Provincial People's Hospital
Lung Cancer
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2…
- Trial name
- NCT06749860
- Testing
- Disitamab Vedotin + tislelizumab + bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Gastric Junction Adenocarcinoma, Gastric Cancer
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer.
- Conditions
- Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
- Trial name
- SNCCTGC (NCT06826079)
- Testing
- Sorbitol + PD-1 inhibitor + SOX chemotherapy, PD-1 inhibitor + SOX chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cholangiocarcinoma Non-resectable
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of Drug-eluting Beads-transarterial chemoembolization (DEB-TACE)…
- Trial name
- CCGLC-009 (NCT06194695)
- Testing
- drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ze-yang Ding, MD
Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic…
- Conditions
- Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
- Trial name
- NCT06871527
- Testing
- fruquintinib + tislelizumab + FOLFOX
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
Muscle-Invasive Bladder Carcinoma
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
This study is designed prospectively to investigate the safety, efficacy and feasibility of cisplatin-based chemotherapy combined with tislelizumab as bladder sparing treatment for patients with muscle invasive bladder cancer…
- Trial name
- NCT04909775
- Testing
- Tislelizumab, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
TPF, Immunotherapy
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NPC is one of the most common malignant tumors in the head and neck region of China. Currently, the main treatment regimen for LA-NPC is radical concurrent chemoradiotherapy combined with induction or adjuvant chemotherapy.
- Conditions
- TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
- Trial name
- NCT06781112
- Testing
- albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Weiwei Zhang
Advanced Solid Tumors
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
This was a dose verification, pharmacokinetic (PK) assessment of products derived from two manufacturing processes and scales (500L-FMP and 2000L-FMP; FMP: Final Manufacturing Process) and indication expansion clinical study of…
- Trial name
- NCT04068519
- Testing
- Tislelizumab
- Where
- 12 sites in China
- Volunteers
- 300 people
- Sponsor
- BeiGene
Non-small Cell Lung Cancer, Consolidation Immunotherapy
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy.
- Conditions
- Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation
- Trial name
- NCT05758116
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Hepatocellular Carcinoma, Oligometastasis
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
- Conditions
- Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
- Trial name
- NCT06550921
- Testing
- ablation of oligometastasis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University